Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations

@article{OReilly2013SputumPI,
  title={Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations},
  author={Philip J. O'Reilly and Patricia L. Jackson and J. Michael Wells and Mark T. Dransfield and Paul D. Scanlon and J. Edwin Blalock},
  journal={BMJ Open},
  year={2013},
  volume={3}
}
Rationale Proline–glycine–proline (PGP), a neutrophil chemoattractant derived from the enzymatic breakdown of collagen, is elevated in sputum of patients with chronic obstructive pulmonary disease (COPD) and may contribute to disease progression. Whether sputum levels of PGP respond to therapy for COPD or predict outcomes is unknown. Objectives We conducted a study ancillary to a multicenter trial of the efficacy of azithromycin treatment for 1 year in preventing COPD exacerbations to test… 
Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD
TLDR
Simvastatin reversed the IL-17A/IL-10 imbalance in the airways and reduced sputum macrophage but not neutrophil counts in patients with COPD.
A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
TLDR
Roflumilast reduces pulmonary inflammation through decreasing prolyl endopeptidase activity and AcPGP and lessens the overall inflammatory burden, which may alter the natural history of COPD, including the risk of exacerbation.
Disease phenotyping in chronic obstructive pulmonary disease: the neutrophilic endotype
TLDR
Intriguingly, recent evidence has linked both of these agents to modulation of the PGP/neutrophil pathway in concert with this exacerbation reduction, suggesting that a neutrophilic endotype is present and amenable to pharmacological targeting.
The matrikine acetyl-proline-glycine-proline and clinical features of COPD: findings from SPIROMICS
TLDR
In COPD, sputum but not plasma AcPGP concentrations are associated with the severity of airflow limitation, small airways disease, emphysema, and risk for severe AECOPD at 1-year of follow-up.
The matrikine PGP as a potential biomarker in COPD.
TLDR
Critically examine both biological and clinical data related to the role of PGP in COPD, with particular focus on its role as a clinical biomarker and potential therapeutic target in disease.
Antibiotic prophylaxis in COPD: Why, when, and for whom?
Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis
Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients
TLDR
NLR is associated with COPD severity and exacerbations, and receiver-operating-characteristic curves showed the optimal cutoff for the baseline NLR in the predicting moderate/severe exacerbation to be 2.7, which was same as the upper quartile points.
The Matrikine PGP in Lung Diseases : A Translational Study
TLDR
A novel role for acPGP in regulating paracellular permeability during inflammatory disease is described and the potential to target this ligand in various disorders characterized by excessive matrix turnover and vascular leak such as ARDS is demonstrated.
...
...

References

SHOWING 1-10 OF 33 REFERENCES
N-α-PGP and PGP, potential biomarkers and therapeutic targets for COPD
TLDR
Inhibition of this pathway may provide novel therapies for COPD directed at the chronic, neutrophilic, airway inflammation which underlies disease progression, and N-α-PGP and PGP may represent novel diagnostic tests and biomarkers for COPd.
Clarithromycin targets neutrophilic airway inflammation in refractory asthma.
TLDR
Clarithromycin therapy can modulate IL-8 levels and neutrophil accumulation and activation in the airways of patients with refractory asthma and may be an important additional therapy that could be used to reduce noneosinophilic airway inflammation, particularly neutrophilic inflammation, in asthma.
Azithromycin for prevention of exacerbations of COPD.
TLDR
Among selected subjects with COPD, azithromycin taken daily for 1 year, when added to usual treatment, decreased the frequency of exacerbations and improved quality of life but caused hearing decrements in a small percentage of subjects.
A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation
TLDR
These studies imply that therapeutic strategies inhibiting LTA4H to prevent LTB4 generation may not reduce neutrophil recruitment because of elevated levels of PGP, which is a biomarker for chronic obstructive pulmonary disease (COPD) and implicated in neutrophils persistence in the lung.
The Presence of a Matrix-Derived Neutrophil Chemoattractant in Bronchiolitis Obliterans Syndrome after Lung Transplantation12
TLDR
It is shown that in addition to increased levels of IL-8, the level of the neutrophil chemoattractant proline-glycine-proline (PGP) is elevated in BOS patient bronchoalveolar lavage (BAL) fluid, and this findings highlight the influence of a matrix-derived neutrophIL chemoATTractant in posttransplantation BOS.
Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial
TLDR
Long term use of low dose azithromycin in young patients with cystic fibrosis has a beneficial effect on lung disease expression, even before infection with Pseudomonas aeruginosa.
Role of macrolide therapy in chronic obstructive pulmonary disease
TLDR
Macrolide antibiotics are macrocyclical lactones that provide adequate coverage for the most frequently identified pathogens in A ECOPD and have been generally included in published guidelines for AECOPD management.
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
TLDR
Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.
...
...